<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Clofarabine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00631</strong>&#160; (APRD00878, DB07554)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed in the U.S. and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra.</p>
<p>Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (<span class="caps">ALL</span>), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Some investigations of effectiveness in cases of acute myeloid leukaemia (<span class="caps">AML</span>) and juvenile myelomonocytic leukaemia (<span class="caps">JMML</span>) have been carried out.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00631/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00631/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00631.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00631.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00631.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00631.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00631.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00631">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Clofarabin</td><td>German</td><td>INN</td></tr><tr><td>Clofarabina</td><td>Spanish</td><td>INN</td></tr><tr><td>Clofarabine</td><td>French</td><td>INN</td></tr><tr><td>Clofarabinum</td><td>Latin</td><td>INN</td></tr><tr><td>Clofarex</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Clolar</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Clofazic</td><td>Raffo</td></tr><tr><td>Clolar</td><td>Genzyme</td></tr><tr><td>Evoltra</td><td>Genzyme</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/purine-analogues">Purine analogues</a></li></ul></td></tr><tr><th>CAS number</th><td>123318-82-1</td></tr><tr><th>Weight</th><td>Average: 303.677<br>Monoisotopic: 303.053445155</td></tr><tr><th>Chemical Formula</th><td>C<sub>10</sub>H<sub>11</sub>ClFN<sub>5</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>WDDPHFBMKLOVOX-AYQXTPAHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Glycosyl Compounds</td></tr><tr><th>Direct parent</th><td>Purine 2'-deoxyribonucleosides and Analogues</td></tr><tr><th>Alternative parents</th><td>Pentoses; Purines and Purine Derivatives; Halopyrimidines; Aminopyrimidines and Derivatives; N-substituted Imidazoles; Aryl Chlorides; Primary Aromatic Amines; Tetrahydrofurans; Oxolanes; Fluorohydrins; Secondary Alcohols; Primary Alcohols; Polyamines; Ethers; Organofluorides; Organochlorides; Alkyl Fluorides</td></tr><tr><th>Substituents</th><td>pentose monosaccharide; purine; imidazopyrimidine; aminopyrimidine; halopyrimidine; aryl halide; primary aromatic amine; aryl chloride; pyrimidine; monosaccharide; n-substituted imidazole; tetrahydrofuran; imidazole; oxolane; azole; secondary alcohol; halohydrin; fluorohydrin; primary alcohol; ether; polyamine; organochloride; organofluoride; amine; organohalogen; primary amine; alcohol; organonitrogen compound; alkyl halide; alkyl fluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the purine 2'-deoxyribonucleosides and analogues. These are compounds consisting of a purine linked to a ribose which lacks an hydroxyl group at position 2.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.</td></tr><tr><th>Pharmacodynamics</th><td>Clofarabine is a purine nucleoside antimetabolite that differs from other puring nucleoside analogs by the presence of a chlorine in the purine ring and a flourine in the ribose moiety. Clofarabine seems to interfere with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by clofarabine, other effects also occur. Clofarabine prevents cells from making DNA and RNA by interfering with the synthesis of nucleic acids, thus stopping the growth of cancer cells.</td></tr><tr><th>Mechanism of action</th><td>Clofarabine is metabolized intracellularly to the active 5'-monophosphate metabolite by deoxycytidine kinase and 5'-triphosphate metabolite by mono- and di-phospho-kinases. This metabolite inhibits DNA synthesis through an inhibitory action on ribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair through competitive inhibition of DNA polymerases. This leads to the depletion of the intracellular deoxynucleotide triphosphate pool and the self-potentiation of clofarabine triphosphate incorporation into DNA, thereby intensifying the effectiveness of DNA synthesis inhibition. The affinity of clofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosine triphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNA repair by incorporation into the DNA chain during the repair process. Clofarabine 5'-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of the pro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading to programmed cell death.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>172 L/m2</li>
</ul></td></tr><tr><th>Protein binding</th><td>47% bound to plasma proteins, predominantly to albumin.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Clofarabine is sequentially metabolized intracellularly to the 5&#8217;-monophosphate metabolite by deoxycytidine kinase and mono- and di-phosphokinases to the active 5&#8217;-triphosphate metabolite. Clofarabine has high affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equal to or greater than that of the natural substrate, deoxycytidine.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Clofarabine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002804" target="_blank">Deoxycytidine kinase</a></li></ul></td><td><a href="/metabolites/DBMET00419">clofarabind-5'-monophosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/422">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Based on 24-hour urine collections in the pediatric studies, 49 - 60% of the dose is excreted in the urine unchanged.</td></tr><tr><th>Half life</th><td>The terminal half-life is estimated to be 5.2 hours.</td></tr><tr><th>Clearance</th><td><ul>
	<li>28.8 L/h/m2 [Pediatric patients (2 &#8211; 19 years old) with relapsed or refractory acute lymphoblastic leukemia (<span class="caps">ALL</span>) or acute myelogenous leukemia (<span class="caps">AML</span>) receiving 52 mg/m2 dose]</li>
</ul></td></tr><tr><th>Toxicity</th><td>There were no known overdoses of clofarabine. The highest daily dose administered to a human to date (on a mg/m<sup>2</sup> basis) has been 70 mg/m<sup>2</sup>/day &#215; 5 days (2 pediatric ALL patients). The toxicities included in these 2 patients included grade 4 hyperbilirubinemia, grade 2 and 3 vomiting, and grade 3 maculopapular rash.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9827</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7369</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8001</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8279</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9144</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.9031</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8291</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5681</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.817</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8462</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8849</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8391</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8499</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9002</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7338
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7723
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2651 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9643
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8304
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Genzyme corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aaipharma.com">AAIPharma Inc.</a></li>
<li><a href="http://www.genzyme.ca">Genzyme Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Intravenous drip</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01097">Leflunomide</a></td><td>Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy.</td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab. </td></tr><tr><td><a href="/drugs/DB00337">Pimecrolimus</a></td><td>Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants.</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Roflumilast may enhance the immunosuppressive effect of Immunosuppressants. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Tacrolimus (topical) may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. </td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use. </li></ul></td></tr></tbody></table>